Gene hunt aims to prevent deadly diabetes drug complication
NCT ID NCT05402579
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study looked at whether a person's genes can help predict their risk of diabetic ketoacidosis (DKA), a life-threatening side effect of SGLT2 inhibitor drugs used for type 2 diabetes. Researchers compared the DNA of 63 patients who had DKA while on the drug to those who did not. The goal is to find genetic markers that could help doctors identify who is most at risk, so they can use these beneficial drugs more safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Joseph's Health Centre (Unity Health Toronto)
Toronto, Ontario, Canada
-
Toronto General Hospital (University Health Network)
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.